BioTuesdays
PDS Biotechnology

HCW starts PDS Biotechnology at buy; PT $7

H.C. Wainwright initiated coverage of PDS Biotechnology (NASDAQ:PDSB) with a “buy” rating and $7 price target. The stock closed at $3.05 on Nov. 4. PDS is developing anti-cancer therapeutics leveraging its proprietary...

Sientra

WB ups Sientra to OP

William Blair upgraded Sientra (NASDAQ:SIEN) to “outperform,” saying the company’s near-to-midterm outlook has stabilized and is improving. The stock closed at $6.77 on Nov. 4. Analyst Margaret Kaczor writes that she...

HCW starts aTyr Pharma at buy; PT $8

H.C. Wainwright launched coverage of aTyr Pharma (NASDAQ:LIFE) with a “buy” rating and $8 price target. The stock closed at $3.73 on Nov. 4. aTyr is developing therapies leveraging resokines, naturally occurring...

Ventripoint names Justin Leushner as CEO

Ventripoint Diagnostics (TSXV:VPT; OTC:VPTDF) appointed Justin Leushner as CEO, replacing Dr. George Adams, who was elected chairman of the board. Mr. Leushner, who was named president of Ventripoint in September, has a...

Subscribe

Sign up to our weekly BioTuesdays newsletter.